TY - JOUR AU - Toniatti, C. AU - Jones, P. AU - Graham, H. AU - Pagliara, B. AU - Dreatta, G. PY - 2014 DA - 2014// TI - Oncology drug discovery: planning a turnaround JO - Cancer Discov. VL - 4 ID - Toniatti2014 ER - TY - JOUR AU - Caponigro, G. AU - Sellers, W. R. PY - 2011 DA - 2011// TI - Advances in the preclinical testing of cancer therapeutic hypotheses JO - Nat Rev Drug Discov VL - 10 ID - Caponigro2011 ER - TY - JOUR AU - Singh, M. AU - Ferrara, N. PY - 2012 DA - 2012// TI - Modeling and predicting clinical efficacy for drugs targeting the tumor milieu JO - Nat Biotechnol VL - 30 ID - Singh2012 ER - TY - JOUR AU - Herter-Sprie, G. S. AU - Kung, A. L. AU - Wong, K. -. K. PY - 2013 DA - 2013// TI - New cast for a new era: preclinical cancer drug development revisited JO - J Clin Invest VL - 123 ID - Herter-Sprie2013 ER - TY - JOUR AU - Vidula, N. AU - Bardia, A. PY - 2017 DA - 2017// TI - Targeted therapy for metastatic triple negative breast cancer: the next frontier in precision oncology JO - Oncotarget. VL - 8 ID - Vidula2017 ER - TY - JOUR AU - Hudis, C. A. AU - Gianni, L. PY - 2011 DA - 2011// TI - Triple-negative breast cancer: an unmet medical need JO - Oncologist. VL - 16 ID - Hudis2011 ER - TY - JOUR AU - Zeichner, S. B. AU - Terawaki, H. AU - Gogineni, K. PY - 2016 DA - 2016// TI - A review of systemic treatment in metastatic triple-negative breast cancer JO - Breast Cancer (Auckl) VL - 10 ID - Zeichner2016 ER - TY - JOUR AU - Hidalgo, M. AU - Amant, F. AU - Biankin, A. V. AU - Budinski, E. AU - Byrne, A. T. AU - Caldas, C. PY - 2016 DA - 2016// TI - Patient-derived xenograft models: an emerging platform for translational cancer research JO - Cancer Discov VL - 4 ID - Hidalgo2016 ER - TY - JOUR AU - Dobrolecki, L. E. AU - Airhart, S. D. AU - Alferez, D. G. AU - Aparicio, S. AU - Behbod, F. AU - Bentres-Ali, M. PY - 2016 DA - 2016// TI - Patient-derived xenograft (PDX) models in basic and translational breast cancer research JO - Cancer Metast Rev VL - 35 ID - Dobrolecki2016 ER - TY - JOUR AU - Lai, Y. AU - Wei, X. AU - Lin, S. AU - Qin, L. AU - Cheng, L. AU - Li, P. PY - 2017 DA - 2017// TI - Current status and perspectives of patient-derived xenograft models in cancer research JO - J Hematol Oncol VL - 10 ID - Lai2017 ER - TY - JOUR AU - Tentler, J. J. AU - Tan, A. C. AU - Weekes, C. D. AU - Jimeno, A. AU - Leong, S. AU - Pitts, T. M. AU - Arcaroli, J. J. AU - Messersmith, W. A. AU - Eckhardt, S. G. PY - 2012 DA - 2012// TI - Patient-derived tumour xenografts as models for oncology drug development JO - Nat Rev Clin Oncol VL - 9 ID - Tentler2012 ER - TY - JOUR AU - Saraiva, D. P. AU - Cabral, M. G. AU - Jacinto, A. AU - Braga, S. PY - 2017 DA - 2017// TI - How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment JO - ESMO Open VL - 2 ID - Saraiva2017 ER - TY - STD TI - Kumar S, Bajaj S & Bodla RB. Preclinical screening methods in cancer. Indian J Pharmacol. 2016;48(5):481-486. ID - ref13 ER - TY - JOUR AU - Sharma, S. V. AU - Haber, D. A. AU - Settleman, J. PY - 2010 DA - 2010// TI - Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents JO - Nat Rev Cancer VL - 10 ID - Sharma2010 ER - TY - JOUR AU - Lee, G. Y. AU - Kenny, P. A. AU - Lee, E. H. AU - Bissell, M. J. PY - 2007 DA - 2007// TI - Three-dimensional culture models of normal and malignant breast epithelial cells JO - Nat Methods VL - 4 ID - Lee2007 ER - TY - STD TI - Verjans E-T, Doijen J, Luyten W, Landuyt B, Schoofs L. Three-dimensional cell culture models for anticancer drug screening: worth the effort? J Cell Physiol. 2017;233(4). https://doi.org/10.1002/jcp.26052. ID - ref16 ER - TY - JOUR AU - Gomez-Roman, N. AU - Stevenson, K. AU - Gilmour, L. AU - Hamilton, G. PY - 2017 DA - 2017// TI - Chalmers a. A novel 3D human glioblastoma cell culture system for modeling drug and radiation responses JO - Neuro-oncology VL - 19 ID - Gomez-Roman2017 ER - TY - JOUR AU - Xu, X. AU - Farach-Carson, M. C. AU - Jia, X. PY - 2014 DA - 2014// TI - Three-dimensional in vitro tumor models for cancer research and drug evaluation JO - Biotechnol Adv VL - 32 ID - Xu2014 ER - TY - STD TI - Zanoni M, Piccinini F, Arienti C, Zamagni A, Santi S, Polico R, Bevilacquia A, Tesei A. 3D tumor spheroid models for in vitro therapeutic screening: a systematic approach to enhance the biological relevance of data obtained. Sci Rep. 2016;6(19103). https://doi.org/10.1038/srep19103. ID - ref19 ER - TY - STD TI - Fang Y & Eglen RM. Three dimensional cell cultures in drug discovery and development. SLAS Discov. 2017;22(5):456–72. ID - ref20 ER - TY - JOUR AU - Antoni, D. AU - Burckel, H. AU - Josset, E. AU - Noel, G. PY - 2015 DA - 2015// TI - Three-dimensional cell culture: a breakthrough in vivo JO - Int J Mol Sci VL - 16 ID - Antoni2015 ER - TY - STD TI - Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig. 2011. https://doi.org/10.1172/JCI45014. ID - ref22 ER - TY - STD TI - Lehmann BD, Pietenpol JA, Tan AR. Triple-negative breast cancer: molecular subtypes and new targets for therapy. Am Soc Clin Oncol Educ Book. 2015. https://doi.org/10.14694/EdBook_AM.2015.35.e31. ID - ref23 ER - TY - JOUR AU - Rhodes, L. V. AU - Antoon, J. W. AU - Muir, S. E. AU - Elliott, S. AU - Beckman, B. S. AU - Burow, M. PY - 2010 DA - 2010// TI - Effect of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk JO - Mol Cancer VL - 9 ID - Rhodes2010 ER - TY - STD TI - Horimoto Y, Arakawa A, Sasahara N, Tanabe M, Sai S, Himuro T, Saito M. Combination of cancer stem cell markers CD44 and CD24 are superior to ALDH1 as a prognostic indicator in breast cancer patients with distant metastases. PLoS One. 2016. https://doi.org/10.1371/journal.pone.0165253. ID - ref25 ER - TY - JOUR AU - Greve, B. AU - Kelsch, R. AU - Spaniol, K. AU - Eich, H. T. AU - Gotte, M. PY - 2012 DA - 2012// TI - Flow cytometry in cancer stem cell analysis and separation JO - J Int Soc Adv Cytometry VL - 81A ID - Greve2012 ER - TY - JOUR AU - Kleinman, H. K. AU - Martin, G. R. PY - 2005 DA - 2005// TI - Matrigel: basement membrane matrix with biological activity JO - Semin Cancer Biol VL - 15 ID - Kleinman2005 ER - TY - STD TI - Benton G, Kleinman HK, George J, Arnaoutova I. Multiple uses of basement membrane-like matrix (BME/Matrigel) in vitro and in vivo with cancer cells. Int J Cancer. 128(8). https://doi.org/10.1002/ijc.25781. ID - ref28 ER - TY - JOUR AU - Kumar, S. AU - Bajaj, S. AU - Babu Bodla, R. PY - 2016 DA - 2016// TI - Preclinical screening methods in cancer JO - Indian J Physiol Pharmacol VL - 48 ID - Kumar2016 ER - TY - JOUR AU - Chanan-Khan, A. A. AU - Swaika, A. AU - Paulus, A. AU - Kumar, S. K. AU - Mikhael, J. R. AU - Rajkumar, S. V. AU - Dispenzieri, A. AU - Lacy, M. Q. PY - 2013 DA - 2013// TI - Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma JO - Blood Cancer J VL - 3 ID - Chanan-Khan2013 ER - TY - STD TI - Ji M, Lee EJ, Kim KB, Kim Y, Sung R, Lee S-J, et al. HDAC inhibitors induce epithelial-mesenchymal transition in colon carcinoma cells. Oncol Rep. 2015. https://doi.org/10.3892/or.2015.3879. ID - ref31 ER - TY - STD TI - Turner TH, Alzubi MA, Sohal SS, Olex AL, Dozmorov MG, Harrell JC. Characterizing the efficacy of cancer therapeutics in patient-derived xenograft models of metastatic breast cancer. Breast Cancer Res Treat. 2017. https://doi.org/10.1007/s10549-018-4748-4. ID - ref32 ER - TY - JOUR AU - Jian, G. -. M. AU - Wang, H. -. S. AU - Zhang, F. AU - Zhang, K. S. AU - Liu, Z. -. C. AU - Fang, R. PY - 2013 DA - 2013// TI - Histone deacetylase inhibitor induction of epithelial-mesenchymal transition via up-regulation of snail facilitates cancer progression JO - Acta Biochim Biophys VL - 1833 ID - Jian2013 ER - TY - JOUR AU - Damaskos, C. AU - Valsami, S. AU - Kontos, M. AU - Spartalis, E. AU - Kalampokas, T. AU - Kalampokas, E. PY - 2017 DA - 2017// TI - Histone deacetylase inhibitors: an attractive therapeutic strategy against breast cancer JO - Anticancer Res VL - 37 ID - Damaskos2017 ER - TY - JOUR AU - Fedele, P. AU - Orlando, L. AU - Cinieri, S. PY - 2017 DA - 2017// TI - Targeting triple negative breast cancer with histone deacetylase inhibitors JO - Expert Opin Investig Drugs VL - 26 ID - Fedele2017 ER - TY - JOUR AU - Shah, P. AU - Gao, Y. AU - Sabnis, G. PY - 2014 DA - 2014// TI - Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin JO - Breast Cancer Res Treat VL - 143 ID - Shah2014 ER - TY - JOUR AU - Rhodes, L. V. AU - Tate, C. R. AU - Segar, H. C. AU - Burks, H. E. AU - Phamduy, T. B. AU - Hoang, V. PY - 2014 DA - 2014// TI - Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators JO - Breast Cancer Res Treat VL - 145 ID - Rhodes2014 ER - TY - JOUR AU - Tate, C. R. AU - Rhodes, L. V. AU - Segar, H. C. AU - Driver, J. L. AU - Pounder, F. N. AU - Burow, M. E. AU - Collins-Burow, B. M. PY - 2012 DA - 2012// TI - Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat JO - Breast Cancer Res VL - 14 ID - Tate2012 ER - TY - STD TI - Gomez-Miragaya J, Palafox M, Pare L, Yoldi G, Ferrer I, Vila S, et al. Resistance to taxanes in triple-negative breast cancer associates with the dynamics of a CD49f+ tumor-initiating population. Stem Cell Reports. 2017;8(5):1392–407. ID - ref39 ER -